Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
Dexcom announced NEJM publication of the CONNECT randomized controlled trial, the first real-time CGM clinical data the journal has published in nearly two decades. Dexcom G7 users not on insulin achieved an average 1.6% A1C reduction from a baseline of 8.8% -- 0.9% better than routine care -- and spent about five additional hours per day in the 70-180 mg/dL target range.
Key figures
- Drug Name
- Dexcom G7
- Phase Of Trial
- Randomized controlled trial (CONNECT)
- Study sites
- 22
- Baseline a1c pct
- 8.8
- A1c reduction pct
- 1.6
- Pct a1c below 7 0
- 46%
- Pct a1c below 7 5
- 68%
- Target range mg dl
- 70-180
- Cgm persistence 26wk
- 97%
- Participants screened
- 440
- Additional hours in range per day
- 5
- Incremental a1c reduction vs care pct
- 0.9
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.